FAF
SRPT icon

Fjarde Ap-fonden’s Sarepta Therapeutics SRPT Stock Holding History

Fjarde Ap-fonden’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27,000
Closed -$2.01M – 573
2021
Q1 		$2.01M Buy
27,000
+600
+2% +$55.4K 0.02% 550
2020
Q4 		$4.5M Buy
26,400
+400
+2% +$59.3K 0.04% 411
2020
Q3 		$3.65M Buy
26,000
+2,300
+10% +$350K 0.04% 433
2020
Q2 		$3.8M Sell
23,700
-2,500
-10% -$340K 0.05% 384
2020
Q1 		$2.56M Buy
26,200
+600
+2% +$68.6K 0.04% 428
2019
Q4 		$3.3M Buy
25,600
+3,000
+13% +$303K 0.04% 465
2019
Q3 		$1.7M Buy
+22,600
New +$2.67M 0.02% 548

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fjarde Ap-fonden's SRPT Position: Q2 2021 in Review

Fjarde Ap-fonden sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 27,000 shares — an estimated $2.01M sold.

Fjarde Ap-fonden first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $4.5M in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Fjarde Ap-fonden reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Fjarde Ap-fonden sold 27,000 Sarepta Therapeutics shares in Q2 2021, an estimated $2.01M.
  • Fjarde Ap-fonden first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
  • Fjarde Ap-fonden's Sarepta Therapeutics position peaked at $4.5M in Q4 2020.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Fjarde Ap-fonden's 13F filing for Q2 2021, filed 12 Aug 2021.